Paid Clinical Trials - 82,000 Members & Growing

  • Sponsored Links
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.


Browse Locations ... United States» ... Indiana» ... Fort Wayne







  • Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Bendamustine;   Drug: Obinutuzumab
    Sponsor:   Genentech, Inc.
    Not yet recruiting - verified December 2014

  • Condition:   Heart Failure
    Intervention:  
    Sponsor:   Boston Scientific Corporation
    Recruiting - verified December 2014

  • Condition:   Dentin Sensitivity
    Interventions:   Drug: Potassium nitrate and sodium fluoride;   Drug: Standard fluoride dentifrice
    Sponsor:   GlaxoSmithKline
    Recruiting - verified December 2014

  • Condition:   Oral Hygiene
    Interventions:   Drug: Sodium bicarbonate plus sodium fluoride;   Drug: Sodium fluoride
    Sponsor:   GlaxoSmithKline
    Recruiting - verified December 2014

  • Condition:   Pelvic Organ Prolapse
    Interventions:   Device: Exair Prolapse Repair System;   Procedure: Total Native Tissue Repair
    Sponsor:   Coloplast A/S
    Recruiting - verified December 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: RTA 408 Lotion 0.5%;   Drug: RTA 408 Lotion 3%;   Drug: Lotion vehicle/Placebo
    Sponsors:   Reata Pharmaceuticals, Inc.;   AbbVie
    Recruiting - verified November 2014

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Hormone-Resistant Breast Cancer;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Exemestane;   Drug: Entinostat;   Drug: Goserelin Acetate;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
    Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
    Sponsors:   AstraZeneca;   The Cleveland Clinic
    Recruiting - verified December 2014

  • Condition:   Brain Ischemia
    Interventions:   Drug: alteplase [Activase];   Drug: alteplase placebo;   Drug: aspirin;   Drug: aspirin placebo
    Sponsor:   Genentech, Inc.
    Recruiting - verified December 2014

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Biological: adalimumab 40 mg;   Biological: sirukumab 100 mg;   Biological: sirukumab 50 mg;   Drug: Placebo
    Sponsors:   Janssen Research & Development, LLC;   GlaxoSmithKline
    Recruiting - verified December 2014

  • Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting - verified December 2014

  • Conditions:   Acute Ischaemic Stroke;   Transient Ischaemic Attack.
    Interventions:   Drug: ticagrelor;   Drug: Acetylsalicylic acid (ASA)
    Sponsor:   AstraZeneca
    Recruiting - verified November 2014

  • Condition:   Asthma
    Intervention:  
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified December 2014

  • Condition:   Multiple Sclerosis
    Intervention:   Drug: TERIFLUNOMIDE HMR1726
    Sponsor:   Sanofi
    Recruiting - verified December 2014

  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: Ibrutinib;   Biological: Rituximab;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Asthma
    Interventions:   Drug: lebrikizumab;   Drug: lebrikizumab;   Drug: placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified December 2014

  • Condition:   Lymphoma
    Interventions:   Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone (or equivalent)
    Sponsors:   Janssen Research & Development, LLC;   Pharmacyclics
    Recruiting - verified December 2014

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Drug: Cabozantinib S-malate;   Drug: Sunitinib Malate;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Idarubicin;   Drug: Vorinostat;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Contraception;   Menorrhagia
    Interventions:   Device: ESS305 (Essure, BAY1454032);   Procedure: NovaSure
    Sponsor:   Bayer
    Recruiting - verified November 2014

  • Condition:   Multiple Sclerosis (MS)
    Interventions:   Drug: Laquinimod 0.6 mg;   Drug: Matching Placebo;   Drug: Laquinimod 1.2 mg
    Sponsor:   Teva Pharmaceutical Industries
    Recruiting - verified December 2014

  • Conditions:   HER2/Neu Positive;   Male Breast Carcinoma;   Metastatic Malignant Neoplasm to the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
    Interventions:   Drug: Lapatinib Ditosylate;   Radiation: Whole-Brain Radiotherapy;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Stroke;   Atrial Fibrillation
    Intervention:  
    Sponsor:   Boehringer Ingelheim
    Recruiting - verified December 2014

  • Conditions:   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage II Grade 1 Contiguous Follicular Lymphoma;   Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Stage II Grade 2 Contiguous Follicular Lymphoma;   Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Stage II Grade 3 Contiguous Follicular Lymphoma;   Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
    Interventions:   Biological: Ofatumumab;   Drug: Bendamustine Hydrochloride;   Drug: Bortezomib;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography with Radiolabeled Targeting Agent;   Radiation: Fludeoxyglucose F-18
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Doxorubicin Hydrochloride;   Drug: Docetaxel;   Drug: Cyclophosphamide;   Biological: Trastuzumab;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Prostate Neoplasms;   Genital Neoplasms, Male;   Urogenital Neoplasms;   Genital Diseases, Male
    Intervention:   Drug: Abiraterone Acetate
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified December 2014

  • Conditions:   Recurrent Thyroid Gland Carcinoma;   Stage I Thyroid Gland Follicular Carcinoma;   Stage I Thyroid Gland Papillary Carcinoma;   Stage II Thyroid Gland Follicular Carcinoma;   Stage II Thyroid Gland Papillary Carcinoma;   Stage III Thyroid Gland Follicular Carcinoma;   Stage III Thyroid Gland Papillary Carcinoma;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma
    Interventions:   Drug: Cediranib Maleate;   Drug: Lenalidomide;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Adenocarcinoma;   Stage IB Esophageal Cancer;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIB Esophageal Cancer
    Interventions:   Radiation: Radiation Therapy;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Trastuzumab;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Olaparib;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   AIDS-Related Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Nodal Marginal Zone Lymphoma;   Post-Transplant Lymphoproliferative Disorder;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Lenalidomide;   Drug: Temsirolimus;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   BCLC Stage C Adult Hepatocellular Carcinoma;   BCLC Stage D Adult Hepatocellular Carcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma
    Interventions:   Drug: Doxorubicin Hydrochloride;   Drug: Sorafenib Tosylate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   Endometrial Serous Adenocarcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Lung Carcinoid Tumor;   Malignant Ovarian Mixed Epithelial Tumor;   Malignant Pancreatic Gastrinoma;   Malignant Pancreatic Glucagonoma;   Malignant Pancreatic Insulinoma;   Malignant Pancreatic Somatostatinoma;   Metastatic Gastrointestinal Neuroendocrine Tumor G1;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Beta Cell Adenoma;   Pancreatic Delta Cell Adenoma;   Pancreatic G-Cell Adenoma;   Pancreatic Polypeptide Tumor;   Recurrent Adult Liver Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Regional Gastrointestinal Neuroendocrine Tumor G1;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer;   Uterine Carcinosarcoma
    Interventions:   Drug: Temsirolimus;   Biological: Bevacizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Anterior Ischemic Optic Neuropathy
    Intervention:   Drug: Diagnostic procedures
    Sponsor:   Bayer
    Recruiting - verified November 2014

  • Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
    Interventions:   Drug: Lenalidomide;   Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Major Salivary Gland Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma;   Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
    Interventions:   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Fluorouracil;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Cytology Specimen Collection Procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Distal Urethral Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma;   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Proximal Urethral Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Urethra Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Regional Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage III Bladder Cancer;   Stage III Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Urethral Cancer;   Ureter Carcinoma
    Interventions:   Drug: Eribulin Mesylate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

PaidClinicalTrials.orgPaidClinicalTrials.org